Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.